[DNA damage repair: An emerging strategy in metastatic prostate cancer]

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Genetic instability is a key factor in cancer development and metastasis.
• Mutations in DNA repair genes, particularly BRCA2 and ATM, are implicated in prostate cancer.
• Current treatments for metastatic castration-resistant prostate cancer (mCRPC) include hormonal therapies and chemotherapy.

Purpose of the Study:

• To explore the role of DNA repair gene mutations in prostate cancer.
• To evaluate the potential of specific therapies targeting DNA repair defects in mCRPC.

Main Methods:

• Review of genetic alterations in prostate cancer, focusing on DNA repair genes.
• Analysis of preliminary data on the efficacy of DNA-damaging agents and PARP inhibitors.

Main Results:

• Approximately 20% of prostate cancer patients harbor mutations in DNA repair genes.
• Early findings suggest that platinum salts and PARP inhibitors show specific activity in patients with these mutations.
• PARP inhibitors demonstrate a notable antitumor response.

Conclusions:

• DNA repair gene mutations are prevalent in prostate cancer.
• PARP inhibitors represent a potential therapeutic strategy for mCRPC patients with DNA repair deficiencies.
• Ongoing clinical trials are investigating this promising treatment avenue.